Accéder au contenu
Merck

Discovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC.

Cell chemical biology (2020-09-24)
Lydia Boike, Alexander G Cioffi, Felix C Majewski, Jennifer Co, Nathaniel J Henning, Michael D Jones, Gang Liu, Jeffrey M McKenna, John A Tallarico, Markus Schirle, Daniel K Nomura
RÉSUMÉ

MYC is a major oncogenic transcriptional driver of most human cancers that has remained intractable to direct targeting because much of MYC is intrinsically disordered. Here, we have performed a cysteine-reactive covalent ligand screen to identify compounds that could disrupt the binding of MYC to its DNA consensus sequence in vitro and also impair MYC transcriptional activity in situ in cells. We have identified a covalent ligand, EN4, that targets cysteine 171 of MYC within a predicted intrinsically disordered region of the protein. We show that EN4 directly targets MYC in cells, reduces MYC and MAX thermal stability, inhibits MYC transcriptional activity, downregulates multiple MYC transcriptional targets, and impairs tumorigenesis. We also show initial structure-activity relationships of EN4 and identify compounds that show improved potency. Overall, we identify a unique ligandable site within an intrinsically disordered region of MYC that leads to inhibition of MYC transcriptional activity.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Copper(II) sulfate, anhydrous, powder, ≥99.99% trace metals basis
Sigma-Aldrich
Tris[(1-benzyl-1H-1, 2, 3-triazol-4-yl)methyl]amine, 97%
Sigma-Aldrich
Biotin picolyl azide
Sigma-Aldrich
Iodoacetamide-13C2, 2-d2, 99 atom % 13C, 98 atom % D
Sigma-Aldrich
EN4-2, ≥98% (HPLC)
Sigma-Aldrich
MISSION® esiRNA, targeting human NRGN